title: Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer.
abstract: The purpose of this analysis was to study the association between the quantity of free circulating DNA and clinical variables in 99 advanced non-small cell lung cancer patients (NSCLC). The quantification in the serum of the gene of the catalytic fraction of telomerase (hTERT) by RT-PCR was used as a reference of the total amount of free DNA in blood. Patients were treated with cisplatin and docetaxel. The median hTERT level for patients in stage IIIB was 70.7 ng/ml vs. 53.1 ng/ml in patients in stage IV (p= 0.35). There was no association between hTERT values and therapy response, 53.9 ng/ml in the complete response (CR) + partial response (PR) group vs. 54.1 ng/ml in the stable disease (SD) + progressive disease (PD) group (p=0.23). In the multivariate analysis, hTERT was an independent predictive variable for time to progression (TTP) Hazard ratio (HR) 2.0, CI 95% 1.2-3.4, p=0.009) and overall survival (OS) (HR 2.4 CI 95% 1.3-4.3, p=0.004). The analysis of TTP and OS with a cut-off of hTERT at 40 ng/ml revealed that patients about this level had statistically poorer TTP (4 vs. 7 months, p= 0.009) and OS (5 vs. 15 months, p<0.0001). In conclusion, in advanced NSCLC, high serum hTERT levels may be a poor prognostic indicator for TTP and OS.
authors.affiliation: Servicio de Oncología Médica, Fundación Investigación, Hospital General Universitario, Valencia, Spain. camps_car@gva.es
authors.forename: Carlos
authors.initials: C
authors.lastname: Camps
authors.forename: Rafael
authors.initials: R
authors.lastname: Sirera
authors.forename: Roy M
authors.initials: RM
authors.lastname: Bremnes
authors.forename: Vanessa
authors.initials: V
authors.lastname: Ródenas
authors.forename: Ana
authors.initials: A
authors.lastname: Blasco
authors.forename: María José
authors.initials: MJ
authors.lastname: Safont
authors.forename: Javier
authors.initials: J
authors.lastname: Garde
authors.forename: Asuncion
authors.initials: A
authors.lastname: Juarez
authors.forename: Cristina
authors.initials: C
authors.lastname: Caballero
authors.forename: Josie Javier
authors.initials: JJ
authors.lastname: Sanchez
authors.forename: Miquel
authors.initials: M
authors.lastname: Taron
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D020134:Catalytic Domain; D004273:DNA, Neoplasm / Q000097:blood*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D015996:Survival Rate; D019098:Telomerase / Q000097:blood / Q000235:genetics*
chemical_list: D004273:DNA, Neoplasm; C509186:TERT protein, human; D019098:Telomerase